Updates from Jim Minow
Jim Minow brings more than 30 years of nonprofit experience in executive management and fundraising to Cure JM Foundation. He served as the Chief Development Officer at the Foundation Fighting Blindness from 2005 to 2014, where he created and implemented programs that doubled annual revenues to $35 million. This funding has supported clinical trials that actually restored vision to the blind.
What we heard was more than promising—it was astounding.
Recently, Cure JM’s Jim Minow was able to attend the Global Conference for Myositis. This conference was not only informational, but was a most impressive day for Cure JM. The conference brings together leading myositis researchers from around the world to share results and collaborate on future projects leading to better care and improved treatments for our JM kids.
Jim notes, “The influence and research leadership our ‘small but mighty’ organization brings to pediatric rheumatology never ceases to amaze me. You, our parents, grandparents, and contributors have created the environment where JM research has flourished in recent years, frankly, because of your forward-looking and generous philanthropy. At a global conference like this, it is incredibly rewarding to see the recognition afforded our truly brilliant research teams you have funded.”
Cure JM held its first post-COVID Family Conference earlier this summer. The conference was an extraordinary experience for families and leaders on so many levels, and I remain in awe of everything this organization has achieved because of the passion you bring to our mission.
I’ve often said that Cure JM is a unique “family of families,” and the importance of being on this JM journey together was never more evident than through the caring and sharing at the conference. I was quite moved by the comment from the Medical Director of a pharmaceutical company in attendance when he said Cure JM was “by far the most family-involved community supporting its children” that his team has ever seen. High praise, indeed, and a validating independent observation as his company is planning a clinical trial for a new myositis therapy that may well include JM patients in the trial protocol.